Colorectal cancer (CRC) is the third most common malignancy and one of the leading
causes of cancer-related death among men worldwide. CRC is a multifactor digestive …

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard
treatment of stage III colon cancer. Combination therapy with fluoropyrimidines and …

Human epidermal growth factor receptor 2 (HER2) is a well-known oncogenic driver in
different tumors and an approved therapeutic target in breast and gastroesophageal cancer …

We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure
accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for …

This study aimed at determining the incidence and clinical implications of HER2 status in
primary colorectal cancer (CRC). HER2 status was investigated in two retrospective cohorts …

Background: Anti-HER2/neu therapy is well-established in breast and gastric carcinoma.
The increased understanding of this pathway led to the identification of new promising drugs …

Despite advances in the treatment of metastatic colorectal cancer (CRC) the 5-year survival
of patients with this disease remains low. A small proportion of CRCs overexpress the HER2 …

Curcumin (diferuloylmethane), which has been shown to inhibit growth of transformed cells,
has no discernible toxicity and achieves high levels in colonic mucosa. 5‐fluorouracil (5‐FU) …

Curcumin (diferuloylmethane), which has no discernible toxicity, inhibits initiation, promotion
and progression of carcinogenesis. 5-Fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) …

Background Colorectal cancer (CRC) is the second most common cause of cancer death
globally. Recent clinical trials suggest an emerging role for HER2 as a potential clinically …